Indivior PLC (INVVY) は上場企業です ヘルスケア セクターの Drug Manufacturers - Specialty & Generic 業界で事業展開. 本社所在地は North Chesterfield, VA, アメリカ. 現CEOは Mark Crossley.
INVVY を有する IPO日 2015-06-09, 1,000 名の正社員, に上場 Other OTC, 時価総額 $3.01B.
Indivior PLC is a specialty pharmaceutical company focused on developing and commercializing medications for opioid use disorder and related mental health conditions. The company markets several buprenorphine-based prescription drugs, including SUBLOCADE, a subcutaneous injection, and the SUBOXONE and SUBUTEX sublingual formulations, alongside legacy products such as Temgesic and Buprenex. With operations across approximately 40 countries and a pipeline addressing opioid addiction and schizophrenia, Indivior combines established product revenues with research collaborations to advance treatment options in addiction medicine. Incorporated in 2014 and headquartered in North Chesterfield, Virginia, the company serves patients and healthcare providers globally.
